Current Evidence and Rationale to Guide Perioperative Management, Including Transfusion Decisions, in Patients With Sickle Cell Disease

Anesth Analg. 2023 Jun 1;136(6):1107-1114. doi: 10.1213/ANE.0000000000006463. Epub 2023 May 19.

Abstract

Sickle cell disease (SCD) is a collection of inherited hemoglobin disorders that results in chronic hemolytic anemia, vaso-occlusion, pain, and end organ damage. Surgery in the SCD population requires careful planning, as perioperative stressors can lead to increased sickling and risk of inducing or further exacerbating vaso-occlusive episodes (VOEs). Additionally, the underlying hypercoagulability and immunocompromised state due to SCD places patients at increased risk of both venous thromboembolism and infection. Judicious fluid administration, temperature regulation, thorough preoperative and postoperative analgesic planning, and preoperative transfusion are all crucial components of decreasing risks of surgery in patients with SCD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Analgesics / therapeutic use
  • Anemia, Sickle Cell* / complications
  • Anemia, Sickle Cell* / diagnosis
  • Anemia, Sickle Cell* / therapy
  • Blood Transfusion / methods
  • Humans
  • Pain / drug therapy

Substances

  • Analgesics